Observational Retrospective Multicenter Study Aimed at Evaluating the Incidence of Hepatitis B Reactivation in Patients Affected by Chronic Lymphocytic Leukemia Treated With Ibrutinib
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Oct 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Lamivudine
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms LLC1618
- 26 Oct 2018 Last checked against the ClinicalTrials.gov record.
- 22 Oct 2018 Planned initiation date changed from 30 Sep 2018 to 1 Dec 2018.
- 03 Aug 2018 Planned initiation date changed from 30 Jun 2018 to 30 Sep 2018.